Physician profile
Ramel Failma
NPI 1457361180
$1,971.31
in general payments reported to CMS, 2019-2025
26 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $361 · 2021: $210 · 2022: $293 · 2023: $289 · 2024: $402 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $827.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $254.08 | 2019-2025 | Andexxa, Farxiga |
| Novo Nordisk INC | $229.13 | 2019-2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $211.66 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $199.89 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $187.28 | 2019-2025 | Verquvo, Capvaxive |
| Novartis Pharmaceuticals Corporation | $160.09 | 2024-2025 | |
| Amgen INC. | $115.91 | 2023-2024 | Repatha, Otezla, Evenity |
| Pfizer INC. | $103.02 | 2019-2023 | |
| Organogenesis INC. | $55.66 | 2023 | Puraply |
| Sanofi-Aventis U.S. LLC | $54.56 | 2022-2023 | |
| Lilly USA, LLC | $49.70 | 2020-2023 | Jardiance |
| Smith+Nephew, INC. | $49.18 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.74 | 2019-2020 | |
| Eisai INC. | $33.94 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $31.51 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $29.44 | 2019 | |
| Dexcom, INC. | $29.12 | 2024-2025 | Dexcom G6 Transmitter |
| Biogen, INC. | $25.07 | 2021-2022 | |
| Exact Sciences Corporation | $19.70 | 2024 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $16.85 | 2021 | |
| Astellas Pharma US INC | $15.80 | 2024 | Veozah |
| Kowa Pharmaceuticals America, INC. | $15.79 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.17 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.22 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.87 | 2022 | |
| Allergan, INC. | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramel Failma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.